Preactive therapeutic drug monitoring (TDM): time to redefine TDM

Konstantinos Papamichaela Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USACorrespondence[email protected]

Nurulamin M. Noorb Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

Adam S. Cheifetza Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

"Preactive therapeutic drug monitoring (TDM): time to redefine TDM." Scandinavian Journal of Gastroenterology, 59(8), pp. 1021–1022

Disclosure statement

K.P.: received lecture fees from Physicians Education Resource LLC and Grifols; scientific advisory board fees: ProciseDx Inc and Scipher Medicine Corporation; and consultant fees from Prometheus Laboratories Inc.; A.S.C.: Consulting: Abbvie, Adiso, Artizan (SAB), Bristol Myers Squibb, Clario, Food is Good, Fresenius Kabi, Fzata, Janssen, Pfizer, Prometheus (SAB), ProciseDx, Spherix, Samsung, Protagonist, Takeda; Speaking (non-branded): Abbvie, BMS; N.M.N.: received educational grants and/or speaker fees from Bristol Myers Squibb, Celltrion, Dr Falk Pharma, Galapagos, Janssen, Lilly, Pfizer, Pharmacosmos, SBK Healthcare, Takeda and Tillotts Pharma AG.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Preactive therapeutic drug monitoring (TDM): time to redefine TDM

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Preactive therapeutic drug monitoring (TDM): time to redefine TDM

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date